Clinical trial

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

NCT05986071

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-05-01

PhasePHASE1 / PHASE2

Study timeline

Study start (estimated)2024-05-01Date precision: day

Registry last updated2024-03-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

M1774DRUG

Fulvestrant injectionDRUG

Sponsors & collaborators

Institut Paoli-Calmetteslead sponsor

National Cancer Institute, Francecollaborator

Merck KGaA, Darmstadt, Germanycollaborator

Mapped research locations

MarseilleFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05986071 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.